This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Elsevier NV | |
|---|---|
| Name | Elsevier NV |
| Type | Private company |
| Industry | Publishing |
| Founded | 1880 |
| Headquarters | Amsterdam, Netherlands |
| Key people | * Leonard William King * John Browne, Baron Browne of Madingley * Michael Schuessler |
| Products | Academic journals, books, databases, analytics |
| Parent | Reed Elsevier |
Elsevier NV is a multinational publishing company specializing in scientific, technical, and medical literature. It operates global journals, digital platforms, and analytics tools used by researchers, libraries, and institutions across United Kingdom, United States, Netherlands, China, and India. The company has been central to debates involving academic publishing, intellectual property, and digital transformation since the late 19th century.
Founded in 1880, the firm emerged during an era of industrial expansion alongside institutions such as Royal Society and American Association for the Advancement of Science. Early developments paralleled publishers like Springer Science+Business Media and Wiley-Blackwell, while contemporaries included Macmillan Publishers and Taylor & Francis. Throughout the 20th century the company expanded via acquisitions including imprints associated with Pergamon Press founders and partnerships with academic societies such as Royal College of Physicians and American Medical Association. In the 1990s and 2000s the firm consolidated titles formerly held by Academic Press and integrated databases used by organizations like National Institutes of Health and Wellcome Trust. Key historical disputes reflected tensions similar to those in cases involving Harvard University, University of California, and consortia represented by Jisc.
The company functions as a division within larger conglomerates historically linked to Reed Elsevier and investors including Bertelsmann-affiliated entities and private equity firms. Executive leadership has had professional ties to boards of organizations such as Royal Society of Chemistry and Institute of Physics. Governance and shareholder relationships have been compared with arrangements at Thomson Reuters and SAGE Publications; regulatory interactions have involved agencies such as European Commission and U.S. Federal Trade Commission. The corporate domicile in Netherlands situates fiscal and legal arrangements near institutions like Dutch Authority for Consumers and Markets.
Operations encompass flagship journals and databases used by researchers at Massachusetts Institute of Technology, Stanford University, University of Oxford, University of Cambridge, and Peking University. Product offerings include peer-reviewed journals comparable to titles at Nature Publishing Group, bibliographic platforms resembling Clarivate services, and clinical tools akin to UpToDate. The portfolio includes specialized journals connected to professional bodies like American College of Cardiology and platforms supporting preprints alongside partners such as bioRxiv and arXiv in collaborative contexts. The company’s editorial processes involve peer reviewers drawn from networks including International Committee of Medical Journal Editors and societies like European Society of Cardiology.
The company's revenue model emphasizes subscription access, licensing agreements with library consortia such as Research Libraries UK, and bundled "big deal" packages. Pricing disputes have paralleled conflicts involving University of California and negotiating bodies like CSU (California State University) and consortia such as Couperin and BiblioCommons. Critics have compared practices to debates around Google Books litigation and antitrust inquiries involving Microsoft. Protests and boycotts have drawn support from academics affiliated with Max Planck Society, Wellcome Trust, and HEFCE.
Legal and regulatory matters have included litigation and investigations akin to high-profile cases involving Elsevier-related plaintiffs (note: company name withheld per constraints) and institutions such as University of California and German Research Foundation. Authorities including European Commission, U.S. Department of Justice, and national competition authorities have examined aspects of contracts, licensing, and market dominance comparable to inquiries that targeted Google and Microsoft in separate industries. Court decisions and policy directives from bodies like Court of Justice of the European Union have influenced access, copyright, and data-mining provisions relevant to publishers and research infrastructures such as Europeana and PubMed Central.
The publisher has participated in open access transformations through agreements with funders and institutions such as Wellcome Trust, Bill & Melinda Gates Foundation, NIH, European Research Council, and national consortia like Project DEAL. It has launched open access journals and hybrid models alongside initiatives comparable to Plan S and infrastructures such as CrossRef and ORCID. Partnerships and negotiations have involved repositories including PubMed Central and Zenodo, while discussions have implicated advocacy groups like SPARC and networks such as Directory of Open Access Journals.
Corporate responsibility programs reference commitments to ethical publishing standards aligned with organizations such as Committee on Publication Ethics, environmental targets similar to those adopted by United Nations Environment Programme signatories, and community engagement with educational institutions like University of Cape Town and University of São Paulo. Sustainability reporting practices intersect with frameworks used by Global Reporting Initiative and investor expectations from entities like BlackRock and Vanguard Group. Philanthropic and training collaborations have been conducted with societies including World Health Organization and NGOs such as Medicines Sans Frontières (Doctors Without Borders).